Pyroptosis
Pyroptosis is a type of programmed cell death that features pore formation on the plasma membrane, cell swelling and plasma membrane disruption. Pyroptosis is a form of lytic programmed cell death initiated by inflammasomes, which detect cytosolic contamination or perturbation.
Gasdermin D (GSDMD), as the executive protein of pyroptosis, is activated and transferred to the membrane to induce glial rupture, resulting in the release of more inflammatory mediators.
Inflammasome is an intracellular signaling complex of the innate immune system. Activation of inflammasomes promotes the secretion of IL-1β/IL-18 and triggers pyroptosis. The proinflammatory effect of IL-1β/IL-18 and pyroptosis contributes to the development of autoimmune and inflammatory diseases.
All Product Categories
-
Pyroptosis Related Products (154)
Related Products (154)
-
Antibodies (1)
-
Related Compound Screening Libraries (1)
-
Pyroptosis Signaling Pathway
-
NLRP3-IN-62
0 ImagesCat. No.: HY-170530CAS No.: 3059965-71-5NLRP3-IN-62 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-62 inhibits pyroptosis in THP-1 cell with an IC50 of 0.7 nM, inhibits IL-β release with an IC50 of 108.5 nM.
-
Ethyl pyruvate (Standard)
0 ImagesEthyl pyruvate (Standard) is the analytical standard of Ethyl pyruvate. This product is intended for research and analytical applications. Ethyl pyruvate is a simple derivative of the endogenous metabolite pyruvate. Ethyl pyruvate is an HMGB1 release inhibitor. Ethyl pyruvate can induce apoptosis by autophagy. Ethyl pyruvate has anti-inflammatory, antioxidant and anti-tumor activity. Ethyl pyruvate can be used in the study of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
-
NLRP3-IN-81
0 ImagesCat. No.: HY-174312CAS No.: 2922814-85-3NLRP3-IN-81 (N102) is a BBB-penetrable inhibitor against NLRP3 inflammasome-dependent pyroptosis with an EC50 of 0.029 μM against cell pyroptosis induced by Nigericin (HY-127019). NLRP3-IN-81 potently inhibits NLRP3-dependent activation of caspase-1 and the release of IL-1β. NLRP3-IN-81 disturbs the interaction of NLRP3 with the adaptor protein ASC and inhibits ASC oligomerization. NLRP3-IN-81 can be used for pyroptosis-related diseases research, such as inflammatory bowel diseases and type 2 diabetes.
-
ICy-OH
0 ImagesCat. No.: HY-150970CAS No.: 2863682-80-6ICy-OH, an iodinated photosensitizer, is an effective anticancer agent. ICy-OH can be used not only for deep tissue imaging (λex=640 nm，λem=690-740 nm) but also to selectively induce cell death in pancreatic cancer cells via cell pyroptosis pathway.
-
ICy-Q
0 ImagesCat. No.: HY-150971CAS No.: 2863682-83-9ICy-Q is a quinone oxidoreductase 1 (NQO-1)-activated near-infrared (NIR) reagent which can react with NQO-1 to release the reduction product ICy-OH. ICy-OH selectively induces pancreatic cancer cell death through the pyroptosis pathway. ICy-Q can be used as an effective tool for rapid and accurate diagnosis of intraoperative pathological sections.
-
Bisdemethoxycurcumin
0 ImagesCat. No.: HY-N2942CAS No.: 52328-96-8Bisdemethoxycurcumin is an orally effective curcuminoid. Bisdemethoxycurcumin downregulates pro-inflammatory cytokines in macrophages by inhibiting the phosphorylation of PI3K/Akt and p38 MAPK. Bisdemethoxycurcumin relieves autophagy inhibition and promotes lipophagy to clear vascular smooth muscle foam cells by inhibiting the PDK1/Akt/mTOR pathway. Bisdemethoxycurcumin activates the cAMP/Epac/AMPKα axis and the NRF2/HO-1 antioxidant axis, thereby indirectly inhibiting the phosphorylation of NF-κB p65 and pro-inflammatory outputs such as IL-1β/IL-6/TNF-α, so as to alleviate pulmonary oxidative stress, inflammatory infiltration and pulmonary edema. Bisdemethoxycurcumin blocks NLRP3-mediated pyroptosis and protects cartilage extracellular matrix degradation by activating NRF2/HO-1. Bisdemethoxycurcumin also exerts a synergistic effect with potassium iodide against Candida.
-
BTF-DNBS
0 ImagesCat. No.: HY-175329BTF-DNBS is a glutathione (GSH)-responsive small-molecule photosensitizer (PS). BTF-DNBS disrupts mitochondrial function and triggers Golgi-mediated pyroptosis, serving as a reactive oxygen species (ROS) generator. BTF-DNBS is promising for research of cancers.
-
ABT-546 hydrochloride
0 ImagesCat. No.: HY-19309CAS No.: 223756-43-2Synonyms: A-216546 hydrochlorideABT-546 (A-216546) hydrochloride is an orally active ETA receptor antagonist, with Ki values of 0.46 nM and 13000 nM for human ETA and ETB receptors, respectively, and exhibits >25000-fold selectivity over the ETB receptor. ABT-546 hydrochloride effectively inhibits ET-1 (HY-P0202)-induced phosphoinositide hydrolysis (IC50 = 0.59 nM) and arachidonic acid release (IC50 = 3.03 nM), and antagonizes ET-1-induced contraction in isolated vascular rings. ABT-546 hydrochloride crosses the placental barrier but shows extremely low fetal exposure, with a favorable safety profile. ABT-546 hydrochloride inhibits ET-1-induced pressor response and downregulates the NLRP3/ROS/GSDMD-mediated pyroptosis pathway. ABT-546 hydrochloride can be used for research on abdominal aortic aneurysm.
-
Garlic oil (synthetic)
0 ImagesCat. No.: HY-N14116ACAS No.: 8000-78-0Garlic oil (synthetic) is an orally effective anti-inflammatory, antioxidant, and anticancer agent. Garlic oil (synthetic) inhibits the activation of NF-κB, NFκB2 and NLRP3 inflammasome, and induces the expression of GSTA1, HO-1 and NQO-1. Garlic oil (synthetic) reduces the Bcl-2/Bax protein ratio and activates NNK-induced apoptosis (apoptosis) in lung tissues. Garlic oil (synthetic) attenuates NNK-induced apoptosis in MRC-5 cells and reduces excessive ROS production. Garlic oil (synthetic) alleviates pyroptosis (pyroptosis) and exerts a protective effect against acute lung injury in mice. Garlic oil (synthetic) inhibits lung tumorigenesis in mice and improves small intestinal motility in rats with type 2 diabetes. Garlic oil (synthetic) can be used in research related to acute lung injury, lung cancer, peptic ulcer, type 2 diabetes and hypertension.
-
Antitumor agent-143
0 ImagesCat. No.: HY-161332Antitumor agent-143 (compound 2c) is an antitumor agent that blocks cell proliferation of A549 cells during the S phase and induces an early apoptosis. Antitumor agent-143 induces cell death via ferroptosis, apoptosis by a ROS-mediated mitochondrial dysfunction pathway and GSDMD-mediated pyroptosis.
-
CQ31
0 ImagesCat. No.: HY-183739CAS No.: 441022-67-9CQ31 is a PEPD and XPNPEP1 inhibitor, with an IC50 of 0.67 μM against PEPD and an IC50 of 122 μM against XPNPEP1. CQ31 inhibits the M24B aminopeptidase activity of PEPD and XPNPEP1. CQ31 induces the accumulation of Xaa-Pro-containing peptides, mildly inhibits DPP8/9, and triggers CASP1-dependent pyroptosis via activation of the CARD8 inflammasome and caspase-1. CQ31 can be used in research related to cancers such as acute myeloid leukemia.
-
NLRP3-IN-26
0 ImagesCat. No.: HY-162013CAS No.: 2927413-30-5
-
FGFR-IN-25
0 ImagesCat. No.: HY-181005FGFR-IN-25 (Compound 19E) is a FGFR inhibitor (IC50s: 1.30 nM and 0.85 nM for FGFR1 and FGFR2, respectively) and radiosensitizer. FGFR-IN-25 effectively reduces the phosphorylation of FGFR1 and its key downstream effectors, pAKT and pERK. FGFR-IN-25 exerts broad-spectrum antitumor activity against gastric cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, triple-negative breast cancer, and glioblastoma. FGFR-IN-25, when combined with radiotherapy, synergistically activates the ROS-Caspase-3-GSDME axis, downregulates PD-L1 expression, and induces immunogenic cell death (ICD). FGFR-IN-25 combined with radiotherapy improves the antitumor efficacy.
-
RR-171
0 ImagesCat. No.: HY-P11935CAS No.: 2410535-57-6RR-171 is an amino acid polypeptide and an inhibitor of the Wnt signaling pathway. RR-171 reduces the expression levels of Wnt-1, GSK3β and β-catenin. RR-171 induces apoptosis (Apoptosis) in pancreatic cancer cells, which is characterized by an increased Bax/Bcl-2 ratio, activation of Caspase-3/7/9, and increased Cleaved-PARP; this pro-apoptotic effect can be partially reversed by Z-VAD-FMK (HY-16658B). RR-171 also induces pyroptosis (Pyroptosis) in pancreatic cancer cells, which is manifested by activation of the NLRP-3 inflammasome, activation of Caspase-1, cleavage of GSDMD, upregulation of IL-1β and IL-18, and increased LDH release; this pro-pyroptotic effect can be partially reversed by VX-765 (HY-13205). RR-171 inhibits the viability, proliferation and colony formation of pancreatic cancer cells, with low cytotoxicity against normal cells. RR-171 downregulates the expression of Ki-67 and PCNA in tumor tissues in vivo, with favorable biosafety. RR-171 can be used in studies related to pancreatic cancer.
-
NLRP3-IN-60
0 ImagesCat. No.: HY-170364CAS No.: 3098827-88-1NLRP3-IN-60 (Compound 39) is the orally active inhibitor for NLRP3. NLRP3-IN-60 inhibits pyroptosis with an IC50 of 13 nM in THP-1 cell. NLRP3-IN-60 inhibits IL-1β release with an IC50 of 225 nM in human whole blood.
-
Relaxin H3 (human)
0 ImagesCat. No.: HY-P4890CAS No.: 1158181-62-4Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
-
Chiisanogenin
0 ImagesCat. No.: HY-N20708CAS No.: 89353-99-1Chiisanogenin is an orally active triterpenoid. Chiisanogenin reduces postprandial blood glucose by promoting GLUT4 translocation and glucose uptake via activation of the IRS-1/PI3K/Akt signaling pathway. Chiisanogenin binds to MLKL and inhibits its phosphorylation and oligomerization, maintains lysosomal integrity, restores autophagic flux, and suppresses NLRP3 inflammasome activation and pyroptosis. Chiisanogenin inhibits xanthine oxidase activity and regulates oxidative stress and ion pump activity. Chiisanogenin binds to or inhibits PKA, H+/K+-ATPase and β-glucuronidase. Chiisanogenin possesses multiple pharmacological activities, including broad-spectrum antibacterial activity, anticancer, anti-inflammatory, antirheumatic, renoprotective, cardioprotective and antiarrhythmic effects. Chiisanogenin can be used in research related to type 2 diabetes, rheumatoid arthritis, myocardial injury, hepatocellular carcinoma and ventricular arrhythmia.
-
Thiolutin (Standard)
0 ImagesThromycin (Standard) is the analytical standard of thromycin (Acetopyrrothin) (HY-N6712). Thiolutin is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin (HY-15142A)-induced cardiotoxicity (DOXIC)[1][2][3][4][5].
-
ECDD-S16
0 ImagesCat. No.: HY-161043ECDD-S16 is a potent inhibitor of pyroptosis. ECDD-S16 inhibits surface and endosomal TLR ligands activated pyroptosis in Raw264.7 cells.
-
Necrosulfonamide (Standard)
0 ImagesCat. No.: HY-100573RCAS No.: 1360614-48-7Necrosulfonamide (Standard) is the analytical standard of Necrosulfonamide (HY-100573). This product is intended for research and analytical applications. Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
